Safety and Efficacy of RUTI® With the Standard of Treatment for Tuberculosis (CONSTAN-ARG)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05455112|
Recruitment Status : Recruiting
First Posted : July 13, 2022
Last Update Posted : January 26, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Tuberculosis, Pulmonary||Biological: RUTI® Vaccine Biological: Placebo||Phase 2|
The safety and immunogenicity of RUTI was established in healthy volunteers, patients with latent tuberculosis (TB); and Drug Susceptible (DS) -TB and Drug resistance (DR)-TB. This study proposed to evaluate the safety and efficacy of the RUTI vaccine in patients with active pulmonary TB. Immunotherapy for TB could shorten the sputum culture conversion, therefore reduce the time required to cure. Therapeutic vaccines do not interfere directly with the causative organism and hence, they are not involved in the development of drug resistance. Therapeutic vaccination would also be beneficial for DS-TB as it could increase the response to the standard therapy and help diminish the development of drug resistance. The vaccination stimulates the immune response during the continuation phase of TB treatment in which the remaining bacteria are poorly sensitive, if not refractory, to antimycobacterial agents, and potentiate chemotherapy. Reducing the huge reservoir of mycobacterium tuberculosis (DS or not) by vaccination strategies could ultimately accelerate elimination of the disease worldwide.
As per the results of the Phase II clinical trial in patients with latent TB, the best polyantigenic response was obtained with a dose of 25µg of RUTI vaccine and the second inoculation did not further increase the response. Based on these findings, a single dose of 25µg of vaccine will be used in the study.
The objective of this study is to i) explore the efficacy as reduction of bacillary load through the study of early bactericidal activity (EBA) in patients with DS-TB; and ii) provide data from safety perspective of the vaccine RUTI (25 µg FCMtb) in patients with TB, when given concomitant with the standard of care treatment initiation.
The study will include patients diagnosed with pulmonary DS-TB, candidate to start treatment with standard-care TB drugs and without any disease that could compromise the assessment of the response to the vaccination, or increase the risk of adverse events. RUTI will be administered on the day of TB treatment start, EBA will be measured on days 2, 4, 7, 10, 12, and 14, and adverse events will be collected up to week 24. Other measurements will be performed to assess the sputum culture conversion (SCC), clinical, X-ray or laboratory worsening, improvement of clinical signs and symptoms, and health-related quality-of-life (HRQOL).
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||44 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Phase IIb Clinical Trial to Evaluate the Efficacy and Safety of the Administration of RUTI® Immunotherapy With the Standard Treatment in Patients With Tuberculosis|
|Actual Study Start Date :||October 29, 2022|
|Estimated Primary Completion Date :||February 2023|
|Estimated Study Completion Date :||July 2023|
Single injection of RUTI 25µg of FCMtb at day 0.
Biological: RUTI® Vaccine
One subcutaneous injection of RUTI 25µg FCMtb
Placebo Comparator: Placebo
Single injection of saline at day 0.
One subcutaneous injection of saline
- Early bactericidal activity (EBA) 0-14 [ Time Frame: From day 0 to day 14 ]Change in EBA, using the time to positivity (TTP) of sputum in liquid Mycobacteria Growth Indicator Tube (MGIT)
- Adverse events [ Time Frame: From day 0 to week 24 ]Proportion of patients with treatment-emergent adverse events (TEAE)
- Grade 3-4 adverse events [ Time Frame: From day 0 to week 24 ]Total number of grade 3 and 4 adverse events (AE)
- Time to sputum culture conversion (SCC) [ Time Frame: From day 0 to week 16 ]Time to SCC, in liquid MGIT
- Proportion of SCC at week 16 [ Time Frame: From day 0 to week 16 ]Proportion of participants with SCC, in liquid MGIT
- Proportion of SCC at week 16 [ Time Frame: From day 0 to week 8 ]Proportion of participants with SCC, in liquid MGIT
- Early bactericidal activity (EBA) 2-14 [ Time Frame: From day 2 to day 14 ]Change in EBA, using the TTP of sputum in liquid MGIT
- Early bactericidal activity (EBA) 7-14 [ Time Frame: From day 7 to day 14 ]Change in EBA, using the TTP of sputum in liquid MGIT
- Early bactericidal activity (EBA) 24 weeks [ Time Frame: From day 0 to week 24 ]Change in EBA, using the TTP of sputum in liquid MGIT
- Proportion of SCC per weeks [ Time Frame: Weeks 4, 12, 16, and 24 ]Proportion of participants with SCC, in liquid MGIT
- Clinical worsening [ Time Frame: From day 0 to week 24 ]Proportion of participants with clinical, X-ray, or laboratory worsening
- Improvement of clinical signs and symptoms [ Time Frame: Weeks 1, 2, 8, 12, 16, and 24. ]Proportion of participants with improvement on Bandim TB score
- Improvement of quality of life [ Time Frame: Weeks 8 and 24 ]Proportion of participants with improvement on health-related quality of life (HRQOL)
- Discontinuation of TB treatment [ Time Frame: From day 0 to week 24. ]Proportion of participants who discontinue treatment due to failure, resistance, other.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Men and women aged 18 or older
- Written informed consent
- Laboratory confirmed pulmonary TB
- Clinical symptoms compatible with pulmonary TB and/or X-ray evidence of pulmonary TB
- Women of non-childbearing potential: at least 2 years post-menopausal or surgically sterile (e.g. tubal ligation)
- Women of childbearing potential (including women less than 2 years past menopause) must have a negative pregnancy test at enrollment and must agree to use dual-barrier methods of contraception, intrauterine device (IUD), bilateral tubal occlusion, sexual abstinence, or vasectomized partner.
- Males must agree to use a double barrier method of contraception at least 1 month after RUTI/placebo vaccination; or the male patient or his female partner must be surgically sterile or the female partner must be post-menopausal
- Willing and able to attend all study visits and comply with all study procedures
- Verifiable address or place of residence easy accessible to perform visits and willing to inform the research team of any change during the treatment and follow-up period
- Unable to provide written informed consent
- Women reported, or detected, or willing to be pregnant during the trial period; Men willing to conceive a child during the study or 6 months after end of treatment
- Severity of illness precluding full evaluation: expected early death, evidenced by respiratory failure, low blood pressure, WHO performance score 3-4
- Evidence or suspicion of resistance to rifampin, isoniazid, pyrazinamide, and ethambutol, either laboratory-confirmed or based on epidemiological history at screening
- Previous treatment for M. tuberculosis in the previous 24 months.
- Bodyweight < 40kg
- Unstable Diabetes Mellitus as a poor metabolic control within the past 12 months
- HIV-infected subjects
- Major co-morbid conditions or any other finding which in the opinion of the investigator would compromise the protocol compliance or significantly influence the interpretation of results
- HIstory of severe mental ilness which, in the opinion of the investigator, may exclude the participant from participating in the trial.
Any of the following laboratory parameters:
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x upper limit of normal (ULN)
- Total bilirubin > 2 x ULN
- Neutrophil count ≤ 500 neutrophils / mm3
- Platelet count < 50,000 platelets / mm3
- Alcohol use: potential participant either self-reports or in the investigator's opinion that the patient drinks more than an average of four units/day over a usual week or is a binge drinker (men: 5 or more drinks; women: consume 4 or more drinks, in about 2 hours)
- Known allergy or any hipersensitivity to study mediactions, including rifampin, isoniazid, pyrazinamide, and ethambutol, or any of its excipients.
- Documented allergy to anti-TB vaccines or any excipient of the RUTI vaccine.
- Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05455112
|Contact: Leylen Colmegnaemail@example.com|
|Hospital José Nestor Lencinas||Recruiting|
|Godoy Cruz, Mendoza, Argentina, M5547|
|Contact: María Andrea Villalba|
|Hospital de Clínicas Presidente Dr. Nicolás Avellaneda||Recruiting|
|San Miguel De Tucumán, Tucumán, Argentina, T4001KKP|
|Contact: Conrado Juan Llapur|
|Responsible Party:||Archivel Farma S.L.|
|Other Study ID Numbers:||
|First Posted:||July 13, 2022 Key Record Dates|
|Last Update Posted:||January 26, 2023|
|Last Verified:||January 2023|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Tuberculosis, immunotherapy, drug-susceptible
Gram-Positive Bacterial Infections
Bacterial Infections and Mycoses
Respiratory Tract Infections
Respiratory Tract Diseases